ATRICURE SYNERGY ABLATION SYSTEM
AtriCure, Inc. · Decision date Dec 14, 2011
What did the FDA approve?
FDA records P100046 as an original PMA application. The recorded decision is approval, dated Dec 14, 2011.
FDA approval order statement
APPROVAL FOR THE ATRICURE SYNERGY ABLATION SYSTEM. THIS DEVICE IS INDICATED FOR THE ABLATION OF CARDIAC TISSUE FOR THETREATMENT OF PERSISTENT ATRIAL FIBRILLATION (SUSTAINED BEYOND SEVEN DAYS, OR LASTING LESS THAN SEVEN DAYS BUT NECESSITATING PHARMACOLOGIC OR ELECTRICAL CARDIOVERSION) OR LONGSTANDING PERSISTENT ATRIALFIBRILLATION (CONTINUOUS ATRIAL FIBRILLATION OF GREATER THAN ONE YEAR DURATION) IN PATIENTS WHO ARE UNDERGOING OPEN CONCOMITANT CORONARY ARTERY BYPASS GRAFTING AND/OR VALVE REPLACEMENT OR REPAIR.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 14, 2011
Regulatory record facts
- Identifier
- P100046
- Regulatory pathway
- Premarket approval application
- Applicant
- AtriCure, Inc.
- Product code
- OCM
- Decision code
- APPR
- Decision date
- Dec 14, 2011
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Surgical cardiac ablation device, for treatment of atrial fibrillation.
- Applicant
- AtriCure, Inc.
- Product code
- OCM
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P100046 received
Application receipt date recorded by FDA.
P100046 · FDA decision
APPR
P100046/S021 · Related supplement
Synergy Ablation System
Timeline entries are records held by MedtechLedger for P100046. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100046
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Synergy Ablation SystemP100046/S021 | AtriCure, Inc. | PMA supplement | Sep 24, 2026 | FDA |
Explore the linked device profile
Other records with product code OCM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
EPi- Sense ST Coagulation SystemP200002/S015 | AtriCure, Inc. | PMA supplement | Sep 24, 2026 | FDA |
| AtriCure, Inc. | PMA approval | Apr 28, 2021 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
AtriCure, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7555 Innovation Way, Mason, OH, 45040
Sources and methodology
- Original FDA record: P100046
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
